Related Experiment Video
Updated: Feb 20, 2026
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
hsCRP and ET-1 expressions in patients with no-reflow phenomenon after Percutaneous Coronary Intervention
Min Liu1, Tian Liang2, Peiying Zhang3
1Min Liu, Xuzhou City Hospital of TCM, Xuzhou 221009, Jiangsu Province, China, Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
Insights
Elevated levels of high-sensitivity C-reactive protein (hsCRP) and endothelin-1 (ET-1) indicate a higher risk of no-reflow phenomenon after percutaneous coronary intervention (PCI). These biomarkers may aid in identifying patients at risk for this complication.
Area of Science:
- Cardiology
- Biomarkers
- Interventional Cardiology
Background:
- The no-reflow phenomenon is a complication following percutaneous coronary intervention (PCI).
- Understanding biomarkers associated with no-reflow is crucial for patient management.
- High-sensitivity C-reactive protein (hsCRP) and endothelin-1 (ET-1) are potential indicators of cardiovascular events.
Purpose of the Study:
- To investigate the expression of hsCRP and ET-1 in patients experiencing no-reflow after PCI.
- To evaluate the diagnostic performance of ET-1 alone and in combination with hsCRP for predicting no-reflow post-PCI.
Main Methods:
- A cohort of 136 patients with single coronary artery disease undergoing PCI were studied.
- Patients were categorized into reflow and no-reflow groups.
- Levels of ET-1 and hsCRP were measured and compared between groups; diagnostic accuracy metrics were calculated.
Main Results:
- Postoperative hsCRP and ET-1 levels were significantly higher in the no-reflow group compared to the reflow group (P<0.05).
- ET-1 levels peaked three hours post-PCI in the reflow group, while hsCRP levels showed distinct decline patterns in both groups.
- ET-1 correlated positively with Corrected TIMI Frame Count (CTFC), and hsCRP showed a negative correlation with serum levels (r=-0.34).
Conclusions:
- Significantly elevated hsCRP and ET-1 levels are associated with the no-reflow phenomenon after PCI.
- These biomarkers demonstrate potential utility in identifying patients at risk for no-reflow.
- Further research can explore the therapeutic implications of targeting these markers.
Objective:
To explore hsCRP and ET-1 expressions in patients with no-reflow phenomenon after percutaneous coronary intervention (PCI).
Methods:
A total of 136 patients with single coronary artery disease receiving PCI were divided into a reflow group and a no-reflow group to compare the level use of ET-1 alone with combined level of ET-1 and hs-CRP in PCI regarding sensitivity, specificity, positive and negative predictive values and accuracy for postoperative no-reflow. The study was conducted between 2014-2016 at our hospital.
Results:
Postoperative levels of ET-1 and hs-CRP in no-reflow group were significantly higher than those of reflow group (P<0.05). ET-1 level of reflow group peaked three hours after PCI and then declined. Serum level of hs-CRP decreased most obviously within three hours after PCI in reflow group and three hours - three days after PCI in no-reflow group. Left ventricular end-diastolic diameters of both groups after PCI were apparently lower than those before PCI, without significant inter-group difference (P>0.05). Left ventricular end-systolic diameters and left ventricular ejection fractions of both groups evidently increased after PCI, without significant inter-group differences either (P>0.05). Corrected TIMI frame count (CTFC) and wall motion score index of reflow group after PCI were significantly lower than those of no-reflow group (P<0.05). ET-1 level was positively correlated with CTFC (P<0.05). Multivariate linear regression showed hs-CRP was negatively correlated with the serum level (P<0.05) (r=-0.34).
Conclusion:
hsCRP and ET-1 levels significantly increased in patients with no-reflow phenomenon.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:21Cardiac Catheterization II: Right Heart Catheterization